Concepedia

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Hyun Don Yun, Dawn K. Schirm, Martin Felices, Jeffrey S. Miller, Craig E. Eckfeldt

Blood Advances · 2019 · 19 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

Key Points Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models. Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.

References

12

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Jeffrey S. Miller, Yvette Soignier, Angela Panoskaltsis‐Mortari et al. · Blood · 2005 · 1.9K citations · Full text

, , +13

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Rizwan Romee, Maximillian Rosario, Melissa M. Berrien-Elliott et al. · Science Translational Medicine · 2016 · 924 citations

, , +17

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 561 citations · Full text

, , +17

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Veronika Bachanová, Sarah Cooley, Todd E. DeFor et al. · Blood · 2014 · 432 citations

, , +16

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, <i>In Vivo</i> Expansion, and Enhanced Function

Daniel A. Vallera, Martin Felices, Ron McElmurry et al. · Clinical Cancer Research · 2016 · 368 citations · Full text

, , +17